R&D News | pharmaphorum

News

Calliditas plans to file rare kidney disease drug Nefecon af...

Swedish biotech Calliditas has announced plans to file its rare disease drug Nefecon with the FDA early next year following positive results from a phase 3 clinical trial.

News

Novo Nordisk to buy Emisphere and diabetes pill tech for $1....

Novo Nordisk has agreed to buy Emisphere Technologies for $1.8 billion, as it continues its quest to develop diabetes medicines that can be taken as pills.

News

Novartis' Ilaris fails in late-stage COVID-19 trial

Novartis’ Ilaris (canakinumab) has failed to produce results in a phase 3 trial, which tested whether it could improve COVID-19 patients’ survival chances without need for mechanical ventil

R&D

Enabling innovation by connecting an ecosystem of partners

COVID-19 has been a shock to the system for every industry, not least pharma, but the sector is already looking at new ways to build resilience for the future.

News

AZ's Q3 results disappoint - but COVID-19 vaccine trial is s...

AstraZeneca has posted an uninspiring set of quarterly results as it gears up for results from its closely watched coronavirus vaccine trial.

News

Kyowa Kirin backs €125m life science fund closed by Fountain...

Ireland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund – 25% ahead of its target – and says it will pump most of the mone

Calliditas plans to file rare kidney disease drug Nefecon af...

Novo Nordisk to buy Emisphere and diabetes pill tech for $1....

Novartis' Ilaris fails in late-stage COVID-19 trial

Enabling innovation by connecting an ecosystem of partners

AZ's Q3 results disappoint - but COVID-19 vaccine trial is s...

Kyowa Kirin backs €125m life science fund closed by Fountain...

Why everyone should care about longevity, with Boyang Wang

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks